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Background: Hepatic arterial infusion (HAI) of chemotherapy requires the implantation of a transcatheter
application system which is traditionally performed by surgery. This procedure, but particularly the adjacent drug
application via pump or port is often hampered by specific complications and device failure. Interventionally
implanted port catheter systems (IIPCS) facilitate the commencement of HAI without need for laparatomy, and are
associated with favorable complication rates. We here present an evaluation of the most important technical
endpoints associated with the use of IIPCS for HAI in patients with primary liver cancers.
Methods: 70 patients (pts) with hepatocellular (HCC, n=33) and biliary tract cancer (BTC, n=37) were enrolled into
a phase II –study. Of those, n=43 had recurrent disease and n=31 suffered from liver-predominant UICC-stage IVb.
All pts were provided with IIPCSs before being treated with biweekly, intraarterial chemotherapy (oxaliplatin,
5-Flourouracil, folinic acid). The primary objective of the trial was defined as evaluation of device-related
complications and port duration.
Results: Implantation of port catheters was successful in all patients. Mean treatment duration was 5.8 months, and
median duration of port patency was not reached. Disease-progression was the most common reason for treatment
discontinuation (44 pts., 63%), followed by chemotherapy-related toxicity (12 pts., 17%), and irreversible device
failure (5 pts., 7%). A total of 28 port complications occurred in 21 pts (30%). No unexpected complications
were observed.
Conclusions: HAI via interventionally implanted port catheters can be safely applied to patients with primary
liver tumors far advanced or/and pretreated.
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Hepatocellular carcinoma (HCC) and biliary tract cancer
(BTC) represent the most common primary liver malig-
nancies, with steadily increasing incidences in Europe
and North America. At first glance, tumors arising from
the liver parenchyma and those developing from the
biliary tract exhibit a number of dissimilarities, such as
differences with regard to incidence and risk factors.
However, both cancers also share a number of features
that allow a combined consideration [1-3].
Surgery and - in small HCCs - orthopic liver trans-
plantation represent potentially curative treatment options,
but the majority of patients with HCC and BTC are diag-
nosed in advanced disease stages. For irresectable patients,
the prognosis is dismal on principle, although recent
studies on medical treatment revealed substantial pro-
gress for both cancer types [4,5]. Despite those encour-
aging results, median survival rates in the respective
trials - where only patients with advanced disease were
included - did not exceed 12 months [6,7] so that
further improvements in the treatment of patients with
advanced BTC and HCC are worthwhile.
One possible explanation for the discouraging results
of chemotherapy in advanced liver cancers may be that
the systemic drug concentrations achieved are not effi-
cient enough to warrant loco-regional tumor control.
Indeed, both BTC and HCC typically remain restricted
to the liver or, at least, liver-predominant even in ad-
vanced disease stages. From a theoretical point of view,
regional chemotherapy approaches may be considered
more effective than systemic drug application in most of
those patients [8,9].
Valid data on this matter are restricted to the ap-
plication of transarterial chemoembolisation (TACE)
in patients with intermediate stage HCC-patients. TACE
can be regarded as current standard for the treatment
of HCC-patients with irresectable, but localized mul-
tinodular HCC with maintained liver function (BCLC
group B) where it yields overall survival rates in the
range of 20 months [8,10,11]. The observation that
TACE achieves better results than transarterial embo-
lization alone [12] supports the hypothesis that the
application of regional chemotherapy relevantly con-
tributes to the overall efficacy of the approach. Data
on the use of drug eluting beeds (DEB) for TACE
further suggest that delayed release of chemothera-
peutic agents in the scope of this approach results in
elevated regional drug concentration [13,14]. As those
are in turn considered causal for the superior clinical
results achieved, one may reason that the efficacy of
chemotherapy application in the scope of TACE is
dose-dependent.
Most patients with advanced BTC or HCC suffer from
severe restriction of liver function and concomitant disease.Therefore, they are not eligible for a combined treatment
with tumor embolisation and regional chemotherapy.
Taking the above-mentioned dose-dependency of re-
gional drug application in the scope of TACE as basis,
one strategy to further improve the outcome of patients
with advanced liver-limited or –predominant BTC and
HCC may be the use of modern regional chemotherapy
approaches in the scope of hepatic arterial infusion
(HAI) [15,16].
HAI of chemotherapy enables repetitive delivery of high
intrahepatic drug concentrations in the absence of syn-
chronous embolisation of liver vasculature with acceptable
toxicity. Extensive experience with the technique has
been gained in patients with isolated liver metastases of
colorectal cancer (CRC). A number of randomized trials
on HAI using FUDR or 5-FU in patients with irresectable
colorectal liver metastases or after liver resection have
been performed since the 1980ies, but achieved incon-
sistent results. Besides inadequate study designs (par-
ticularly in the older trials) technical problems with the
application devices employed appear as major reasons
why the method failed to become a standard treatment
outside of clinical trials [17-19].
During the past decade, the feasibility of HAI was rele-
vantly improved by the introduction of interventionally
implanted port catheter systems (IIPCS). IIPCS enable
initiation of HAI without laparatomy, and are associated
with favourable complication and failure rates [20-22].
Most experiences with the technique have again been
gained in patients with colorectal liver metastases [22],
and it has not been thoroughly investigated in patients
with primary liver cancers so far.
In order to further define practicability and safety of
our HAI-approach applied via IIPCS we included pa-
tients with advanced HCC and BTC in a phase 2-trial in
which technical endpoints (complication rates, safety of
device and regional therapy) were defined as primary
objectives. The intraarterial chemotherapy schedule con-
sisting of oxaliplatin, folinic acid, and 5-flourouracil (OFF)
was firstly evaluated in patients with colorectal liver metas-
tases. As 5-FU or its oral prodrug capecitabine combined
with Oxaliplatin are drugs considered particularly effective
in patients with advanced BTC [23,24], we wanted to
evaluate the efficacy and safety of HAI with oxaliplatin
and 5-fluorouracil/folinic acid (OFF) in patients with
liver predominant disease. For HCC, more recent data
showed efficacy for the intraarterial application via HAI
if 5-FU alone or in combination with the platinum-
derivate cisplatin [16,25].
Herein, we report our experience with the regional
OFF regimen via HAI in a larger cohort of patients with
advanced, irresectable BTC/HCC, focusing our presenta-
tion on the primary study objectives “complication rates”
and “safety of device and regional therapy”.
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Study design, patients´ collective and eligibility criteria
Patients with primary liver cancer were prospectively
enrolled into a phase II-study on the evaluation of technical
complications associated with the use of interventionally
implanted port catheter systems (IIPCS) in patients with
cancers confined to the liver between 2004 and 2010
(ClinicalTrials.gov Identifier: NCT00356161). The proto-
col was approved by the local ethics committee (EC of the
Charité University Clinic, Berlin, Germany), and a detailed
written informed consent was obtained from every patient
prior to treatment.
Adult patients were eligible if they had histologically
proven, irresectable, primary or recurrent hepatocellular
cancer (HCC) or intracellular cholangiocarcinoma (ICC),
an ECOG performance status of 0–2, an estimated life
expectancy of ≥ 3 months, and no contraindication against
the initiation of hepatic arterial infusion of chemotherapy.
Main exclusion criteria were evident extrahepatic mani-
festations (abdominal lymph nodes > 25 mm, pulmonary
lesions > 15 mm), severe alteration of liver function (cir-
rhosis, prothrombin time<50%), active viral hepatitis,
portal vein thrombosis, previous liver irradiation, im-
paired coagulation, significant concomitant disease, his-
tory of second malignancy. Previous chemotherapy was
no exclusion criterion for this study.
Primary objective was the evaluation of technical end-
points associated with the use of IIPCS for the applica-
tion of HAI, comprising complications associated with
port implantation and adjacent regional chemotherapy,
port duration (defined as time to port occlusion), and
reasons for primary and secondary device failure. Sec-
ondary endpoints included the evaluation of a standard-
ized approach of chemotherapy application according to
the different treatment indications, chemotherapy tox-
icity, response and survival rates. This report refers to
the evaluation of the primary endpoint of the study for
the subgroup of patients with primary liver cancer (e.g.
hepatocellular and intrahepatic cholangiocellular cancer).
The port implantation procedure was performed as
previously described in detail by Ricke et al. ([21]). A
standard angiography catheter was placed in the hepatic
artery and subcutaneously connected to a port system
(Titakath; Innovent, Hürth, Germany) inferior to the groin,
using a titanium connector (Arrow, Reading, PA, USA).
Functionality of the system was examined by digital subtrac-
tion angiography (DSA), and by requirement complemented
by a scintigraphy using (99m)Tc-labelled macroaggregated
albumin. If significant extrahepatic perfusion was detected
after primary successful implantation of the IIPCS, treat-
ment was interrupted. The device was revised if this
appeared promising from the view of the interventional
radiologist and the patient had responded to treatment.
DSA was repeated before each treatment course.Interventions
Hepatic arterial infusion of chemotherapy
Patients with primary liver cancer received a biweekly
combination therapy of intraarterial oxaliplatin (85 mg/m2,
diluted in 50 ml glucose 5%, 120 minutes), followed by
an intraarterial mixture of natriumfolinate (170 mg/m2)
and 5-FU (600 mg/m2, both diluted in 50–100 ml saline,
120 minutes; regional “OFF”-schedule). For 5-FU, a dose-
escalation of 10% per cycle was performed until the oc-
currence of adverse reactions (WHO I-II). Supportive
treatment consisted of a standard antiemetic regimen
(Dexamethasone, HT3-Antagonist). The port system was
flushed with 10 ml glucose 5% after the application of
oxaliplatin, and blocked with either 5000 units unfrac-
tionated heparine or 3000 anti-Xa units Nadroparine di-
luted in 5 ml of saline after every application. Data on
the feasibility and toxicity of the regional chemotherapy
schedule has been previously published in [21,22].
Evaluations
Pretreatment evaluation and follow-up
Each patients´ history was recorded, and clinical exam-
ination and routine laboratory status were performed
within the 14 days preceeding the first chemotherapy
application. Basic imaging consisted of an abdominal
CT or MRT and chest-X-ray or CT. Clinical evaluation,
a full blood count and clinical chemistry were repeated
before every HAI-application. Assessment of toxicity was
performed according to WHO-criteria.
Response evaluation was performed according to WHO
criteria and repeated in 3-monthly intervals. After the
end of treatment, patients were seen at least every 3
months. Follow-up consisted of clinical visits, laboratory
and imaging until disease progression, initiation of salvage
treatment or death. The efficacy analyses included object-
ive response rates, as well as, progression free- and overall
survival.
Treatment was interrupted in case of irreversible loss
of port function, WHO toxicity of grade IV (except for
haematotoxicity), or disease progression after escalation
of treatment. The drug dosages were reduced if WHO-
toxicity III° or haematotoxicity III/IV° appeared in be-
tween of two treatment courses, or if toxicity >WHO I°
was ongoing on the first day of the following cycle (ex-
cept for leukopenia: >WHO II° and thrombopenia: >II°).
For combination regimens, it was at the physicians dis-
cretion to reduce the dose of all compounds or only of
one drug.
Port complications, port duration, and toxicity
Port-related adverse events were assessed from the date
of successful implantation. Patency and integrity of
the port system was documented by DSA, complemented
by a scintigraphy of the liver with Tc-99m labeled
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were observed. Port duration was defined as functional
device with or without revision, but without require-
ment for explantation of the entire system. Patients in
which HAI was stopped because of disease progression
were censored at the last application of HAI.
Statistical evaluations
Differences between proportions were analyzed by using
chi-square tests. Mann–Whitney tests were employed to
compare quantitative and ordinal variables. The univari-
ate analyses of port duration were calculated according
to the Kaplan-Meier method, and comparisons between
groups were calculated by using Log-Rank tests. A two-
sided p-value less than 0.05 was considered to prove
significance for all tests performed. All analyses were
performed by using the SPSS 18.0 software package.
Results
Patients’ characteristics, treatment characteristics,
and efficacy
Between 2004 and 2010, a total of 70 pts with primary
liver cancers were enrolled (n=33 HCC, n=37 ICC).
Most patients had recurrent disease and were pretreated
by resection, chemotherapy, interventional procedures,
or more than one of those modalities. Five patients with
HCC had previously undergone orthopic liver trans-
plantation (Table 1).
Port implantation was successful and regional therapy
was initialized in all patients, e.g. no case of primary port
failure occurred. Disease progression was the most com-
mon reason for treatment termination (n=44), followed
by chemotherapy-toxicity as second leading cause (n=12).Table 1 Patients’ characteristics
Characteristics n (Total n=70)
HCC (n=33) ICC (n=37)
Age (median/range) 66 (38–76) 59 (41–79)
Gender (f/m) 8/25 22/15
Primary tumour:
Primary/recurrent 8/25 19/18
Grading (G1/G2/G3/n.a.) 1/11/20/12 3/17/7/10
Child-Pugh class A/B/C/n.a. 25/3/1/4 –
Stage IVb 10 21
Pretreatment:
Hepatic resection 18 12
Liver transplantation 5 0
Sorafenib/Chemotherapy 1 6
Chemoembolisation 12 1
Local ablation (RFA, brachytherapy) 2 2
Elevated AFP/Ca 19-9 24 32Only a minority of patients (n=5) had to stop HAI due to
irreversible port dysfunction. There number of device-
related complications was acceptable (28 episodes in 21
patients), revisions of the device were required in 15 pa-
tients (Table 2).
Port-related complications mostly consisted of vascu-
lar events, typically subtotal thrombosis of the hepatic
artery or one of its branches, or dislocation of the cath-
eter tip. Non-vascular problems were less frequent, but
infections of the port chamber accounted for most of
the treatment-limiting port-complications (Table 3a
and b). In one patient, disease progression after intraarterial
chemotherapy was associated with deterioration of por-
tal hypertension and, consecutively, fatal gastrointes-
tinal haemorrhage. This patient had undergone revision
of his IIPCS due to dislocation of the catheter tip and
infection of the port chamber two days before.
Patient received a median of 6 chemotherapy applica-
tions. Median treatment duration was 3.9 months. Median
duration was of port patency was not reached. Rates of
patients with functional devices at 12 months were 13%
(Figure 1). Median time to progression was 5.8 months,
and overall survival was 9.0 months.Chemotherapy toxicity
A total of 41 WHO grade 3/4 adverse events (AEs) were
recorded regardless of their causality to treatment and
occurred in 30 patients (43%) as follows: Infection n=15,
abdominal pain or bleeding n=7, diarrhoe n=6, haemato-
logical n=5, polyneuropathy n=1, others n=7. In 12 patients
(17%) severe AEs were causally related to chemotherapy
and thus resulted in treatment interruption (Table 2).Table 2 Treatment characteristics
Number of patients 70
Number of treatment cycles 562
Range 1-34
Mean 8
Reason for termination of HAI
Disease progression
(intrahepatic n=11, extrahepatic n=16, both n=17)
44 (63%)
Chemotherapy-related toxicity 12 (17%)
Port complication 5 (7%)
Post-progression HAI 4 (6%)
Refusal 4 (6%)
Loss of follow up 1 (1%)
Port complications per patient
≥1 complication 21 (30%)
≥3 complications 3 (4%)
≥ 1 revision 15 (21%)
Table 3 Port complications
a) Overall complications
Abs. %
Number of complications 28 100
vascular 17 61
Dislocation of catheter tip 7 25
Thrombosis 8 29
Reflux 2 7
non vascular 11 39
Leakage 2 7
Infection of port chamber 7 25
others 2 7
b) Treatment -limiting complications
Abs. %
Number of complications 5 100
vascular
Thrombosis 1 20
non vascular
Infection 4 80
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The study collective evaluated herein consists of a heter-
ogenous group of 70 patients suffering from hepatocellu-
lar or intrahepatic cholangiocellular cancer with liver-
limited or liver-predominant disease. For most of them
no established treatment option was available. Patients
were provided with an IIPCS and adjacent HAI usingCu
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Figure 1 Kaplan-Meier estimation of cumulative port patency.oxaliplatin, folinic acid, and 5-FU (regional “OFF”-
schedule) in the scope of a study that was intentionally
designed for technical endpoints in order to get a more
detailed insight into the practicability of the approach.
Thus we were able to give a detailed description on the
technical aspect of HAI applied via IIPCS in primary
liver cancer for the first time. Results obtained in the first
phase of this research program referred to the treatment
of patients with colorectal liver metastases and have
already been reported [22].
It was found that implantation of IIPCS was feasible in all
patients, and that the rate of device related-complications
was relatively low. In addition, the proportion of patients
with treatment discontinuation due to port-failure com-
pares favourably to our previously reported experience in
colorectal liver metastases, and the same holds true for
the Kaplan-Meier estimation of overall port patency
[22,26]. In the interpretion of these results one has to
consider the short average treatment duration. Indeed,
when calculating overall port patency as given in Figure 1,
as much as 21 patients were censored within the first
6 months of treatment, and the rate of devices func-
tioning at 12 months was only 13%. This clearly reflects
that disease progression preceded port failure in the
majority of patients. However, our findings on progression-
free and overall survival may suggest a certain activity of
regional chemotherapy that will be further analysed and
reported in a separate publication.
Another finding of importance may be our observation
that the high proportion of patients suffering from pre-onths
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teract successful port implantation and regional chemo-
therapy. Even though we and others already demonstrated
that HAI administered via IIPCS is feasible and at least
non-inferior when compared with surgically implanted
systems in a nonrandomised fashion [22,27,28], these
data refer to patients with colorectal liver metastases -
and thus to an entity which is usually characterised by
the absence of primary liver disease. Thereby, our results
support the hypothesis that HAI via IIPCS can be also
applied to patients with liver neoplasms suffering from
recurrent disease, high tumour burden, and/or cirrhosis.
We observed grade 3 and 4 adverse events in 43% of
patients enrolled, and treatment interruptions due to
grade 3 and 4 toxicity were required in 17% of patients.
In the pivotal studies on sorafenib in HCC [7] grade 3 or
4 toxicity per patient was reported in 54% (placebo arm)
and 52% (sorafenib arm) of patients treated. The respective
percentages for cisplatin/gemcitabine [25] were 69
(gemcitabine) and 71 (gemcitabine/cisplatin). It seems that
a high proportion of patients with advanced liver cancers
(e.g. 54% in the placebo arm of the HCC-trial) will become
symptomatic without treatment in a considerable short
period of time, and that the application of standard chemo-
therapy does not relevantly improve this rate. In the light of
those data our rates of severe adverse events appear
acceptable.
Discussing our finding in the context of the literature,
we already mentioned in the introduction that most data
available on the use of transcatheter techniques in pri-
mary liver neoplasms so far refer to the application of
transarterial chemoembolisation (TACE) [29-32]. The
few disease-specific trials on HCC-patients treated by
hepatic arterial infusion without synchronous use of
embolising agents employed repetitive catheterisation
techniques [25] or IIPCS [33]. In the latter, HAI using
5-FU and cisplatin was administered to 52 patients with
advanced HCC, and one failure of the IIPCS was reported
that was caused by thrombosis of the hepatic artery. The
experience on HAI in patients with BTC is also limited,
although first studies already date back to the 1980ies
[34]. One recent series on 11 patients treated with HAI
via IIPCS did not explicitly state on the device-related
complications observed, whereas irreversible dysfunc-
tion was reported in 5 out of 16 patients in another one
[35,36]. Two further trials in which patients with both
HCC and ICC were included and treated with HAI applied
via surgically implanted pumps have recently reported by
the workgroup of the Memorial Sloan Kettering Cancer
Center [15,37]. Postoperative complications were observed
in 8 out of 34 (23,5%) in the first, and in 4 out of 56 (7,1%)
in the second of these studies.
To sum it up, the experience with the use of HAI in
primary liver neoplasms is still very limited and is stillfar removed from representing an established treatment
option. Data available did not report on excess technical
problems so that our results support the assumption
that that the use of IIPCS is practicable and safe in pa-
tients with advanced liver neoplasms. But even if pro-
gress of minimally-invasive techniques has considerably
simplified the application of intraarterial transcatheter ther-
apies during the past decade, this is not reflected by a
higher number of clinical trials published on HAI for any
indication. In colorectal liver metastases – the main
field of HAI-application in the 5-FU-era – a rapid pro-
gress in drug development took place during the past 15
years, and studies on HAI did not manage to keep up with
this. In HCC and BTC, recent studies on systemic drug
therapy produced the first considerable progress in med-
ical treatment for these neoplasms for the past 30 years,
but there remains a substantial need for the improvement
of treatment results.
Hepatic arterial infusion in patients with primary liver
neoplasm has a striking rationale, because it enables the
application of high drug concentrations without corre-
sponding increase in overall toxicity. The introduction
of interventionally implanted application systems largely
facilitated the initiation of regional chemotherapy. Our
results support the hypothesis that HAI via IIPCS is safe,
and requires further evaluation in patients with primary
liver cancers.
Conclusions
Hepatic arterial infusion via interventionally implanted
port catheters can be safely administered to a prospect-
ive collective of patients with liver tumors, including a
high proportion of patients with recurrence, high tumor
burden and/or cirrhoses.
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